Strides Pharma plans to disrupt high-volume insulin analogue space with in-house technology
Strides Pharma Science expects to disrupt the high-volume insulin and analogues space with high-speed filling technology developed in-house to delive
Buy Strides Pharma Sciences; target of Rs 864: Sharekhan
Sharekhan is bullish on Strides Pharma Sciences recommended buy rating on the stock with a target price of Rs 864 in its research report dated October 29, 2020. Strides Pharma Science Ltd - 532531 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 30, 2020 for Pronomz Ventures LLP , Arunkumar Pillai & Agnus Holdings Pvt Ltd
Ant Group's Shanghai retail book listing 872 times oversubscribed
Ant is poised to raise about $17.2 billion on Shanghai's STAR Market and roughly the same in Hong Kong, shattering the record set by Saudi Arabian Oil Co
Earnings Call for Q2FY21 of Strides Pharma Science
Conference Call with Strides Pharma Science Management and Analysts on Q2FY21 Performance and Outlook. Listen to the full earnings transcript. Strides Pharma Science Ltd - 532531 - Intimation Pursuant To Regulation 31A Of Sebl (Listing Obligations And Disclosure Requirements) Regulations, 2015
We would like to inform that Board of Directors of the Company in their meeting held on October 29, 2020 have considered and approved the request received from SeQuent Scientific Limited (SeQuent) for reclassification from 'Promoter Group' to 'Public' Category'. Please note that currently, SeQuent does not hold any shares in the Company and the reclassification will not impact the overall promoter holding in the Company. The Company shall seek shareholders' approval for the reclassification in line with the provisions of Regulation 31A of SEBI Listing Regulations. As required under SEBI Listing Regulations, we also enclose herewith extract of the minutes of Board Meeting for your perusal. Request you to kindly take the same on record and oblige. Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Scheme of Arrangement
Update on intimation of Scheme of Amalgamation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 filed on January 30, 2020 Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
The Board of Directors of the Company in their meeting held today have allotted 9,750 equity shares of face value of Rs. 10/- each to the eligible employees who have exercised their stock options under Strides ESOP 2016 Plan. These shares shall rank in pari passu with the existing equity shares of the Company in all respects. Consequent to above, the paid-up share capital of the Company has increased from Rs. 89,62,56,640/- consisting of 8,96,25,664 equity shares of Rs. 10/- each to Rs. 89,63,54,140/- consisting of 8,96,35,414 equity share of Rs. 10/- each. Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) For The Quarter And Half Year Ended September 30, 2020
We are pleased to enclose the Unaudited Financial Results (Standalone and Consolidated) of the Company along with Limited Review Report of the Statutory Auditors for the quarter and year ended September 30, 2020, as approved by the Board of Directors of the Company at their meeting held today, along with a press release issued in this regard. The board meeting commenced at 11:00 hrs and concluded at 12:15 hrs. This is for your information and record.